Novel radioiodinated desvenlafaxine‐loaded lipid nanocapsule for brain delivery

Lipid nanocapsules (LNCs) are lipid nanocarriers developed for drug delivery enhancement. The antidepressant drug desvenlafaxine (DSV) was entrapped in LNC to improve its brain delivery. Different DSV‐loaded LNCs formulae using different oils and surfactants were studied to obtain the optimum formula for further studies. In vivo biodistribution studies were done using Swiss albino mice by intravenous injection of DSV‐loaded LNCs by radioiodination technique. The optimum DSV‐loaded LNC formula was obtained by using Labrafil® M1944CS as the oil and Solutol® HS15 as the surfactant in the ratio of 1:1, with a particle size of 34.28 ± 0.41 nm, a polydispersity index of 0.032 ± 0.05, a zeta potential of −25.77 ± 1.41, and good stability for up to 6 months. The in vivo biodistribution and pharmacokinetics data ensure the bioavailability improvement for DSV brain delivery as Cmax and AUC(1–t) increased more than double for intravenously DSV‐loaded LNCs compared with the DSV solution. In conclusion, the results obtained from this study give an insight into the great potential of using DSV‐loaded LNC for the enhancement of brain delivery. The antidepressant drug desvenlafaxine (DSV) was entrapped in lipid nanocapsules to improve its brain delivery. The in vivo biodistribution and pharmacokinetics data demonstrated the bioavailability improvement for DSV brain delivery.